NCT00469326

Atorvastatin Pre-Treatment Influences the Risk of Percutaneous Coronary Intervention Study

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 200 (actual)
• Sponsor: University Hospital, Motol · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

This study investigates potential protective effect of atorvastatin pre-treatment in patient with stable coronary artery disease undergoing percutaneous coronary intervention (PCI). Patient are randomized to two groups: atorvastatin pre-treatment group (80mg atorvastatin two days before PCI) and control group (PCI without atorvastatin pretreatment). Endpoint is myocardial infarction measured by troponin I and creatine kinase myocardial band.

Detailed description

Randomized studies have shown that pre-treatment with atorvastatin may reduced periprocedural myocardial in patient with stable angina during elective PCI. These data provide evidence-based support for using atorvastatin 7 days before PCI (dosage 40mg/d), alternatively three or more days (unknown dosage). We want to confirm this results for shorter pre-treatment period (two days) with dosage 80mg per day.

Conditions

• Coronary Artery Disease

Interventions

Type	Name	Description
DRUG	Atorvastatin	two days 80mg atorvastatin pre-treatment before PCI

Timeline

• Start date: 2005-04-01
• Primary completion: 2008-12-01
• Completion: 2008-12-01
• First posted: 2007-05-04
• Last updated: 2009-01-27

Locations

1 site across 1 country: Czechia